ALK and non-small cell lung carcinoma: However, it has been discovered that patients with ALK fusion NSCLC who develop compound ALK TKD mutations while receiving treatment exhibit decreased sensitivity to lorlatinib and clinical development (Shiba-Ishii et al., 2022).